WebAug 31, 2011 · To evaluate initial bivalirudin dosing requirements in patients with and without renal dysfunction, including patients on different forms of dialysis. Methods: A … WebThe efficacy of bivalirudin has been well documented in the setting of percutaneous coronary intervention, but there are only few data on its use in chronic dialysis-dependent patients. Bivalirudin is mainly eliminated enzymatically (80%) and …
Frontiers Management of Bivalirudin Anticoagulation Therapy …
WebApr 10, 2024 · A major advancement in the field of medicine has been the introduction and usage of direct oral anticoagulants (DOACs) such as dabigatran (Pradaxa), apixaban (Eliquis), and rivaroxaban (Xarelto). DOACs have been increasing in popularity for mainstay anticoagulation pharmacotherapy and are being preferred by physicians over warfarin … WebSep 15, 2024 · Bivalirudin is a prescription medicine used to treat the symptoms of Percutaneous Coronary Intervention. Bivalirudin may be used alone or with other medications. Bivalirudin belongs to a class of drugs called Anticoagulants, Cardiovascular; Anticoagulants, Hematologic. It is not known if Bivalirudin is safe and effective in children. diane winchester myrtle beach
Management of heparin-induced thrombocytopenia: systematic reviews and ...
WebApr 11, 2024 · In the United States, about one million people are seen to visit the operating theater for cardiac surgery annually. However, nearly half of these visits result in complications such as renal, neurological, and cardiac injury of varying degrees. Historically, many mechanisms and approaches have been explored in attempts to reduce injuries … WebApr 13, 2024 · BRIGHT-4 (Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI) randomised 6,016 PPCI patients from 63 Chinese centres in open-label fashion to Bivalirudin bolus plus infusion for a median of 3 h versus UFH bolus . Patients underwent predominantly radial PPCI (93%) without any prior thrombolytic, … WebNov 16, 2005 · Bivalirudin was initiated by continuous intravenous infusion (range 0.03–0.2 mg/kg/h) and adjusted to an aPTT of 1.5–2.5 times patient baseline. The mean infusion rate was 0.1 mg/kg/h. The average duration of therapy was 7.8 (range 1–24) days. 7/42 (16.7%) of patients had overt bleeding and received ≥ 2 units of packed red blood cells ... diane winger author